Myriad Genetics, Inc. (MYGN) |
18.63 0.03 (0.16%) 04-24 16:00 |
Open: | 18.54 |
High: | 18.84 |
Low: | 18.37 |
Volume: | 466,732 |
Market Cap: | 1,674(M) |
PE Ratio: | -5.86 |
Exchange: | NASDAQ Global Select |
Industry: | Medical - Diagnostics & Research |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 22.72 |
Resistance 1: | 21.00 |
Pivot price: | 19.43 |
Support 1: | 18.21 |
Support 2: | 15.15 |
52w High: | 24.21 |
52w Low: | 13.82 |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
EPS | -3.180 |
Book Value | 8.710 |
PEG Ratio | -112.87 |
Gross Profit | 0.000 |
Profit Margin (%) | -34.96 |
Operating Margin (%) | -12.56 |
Return on Assets (ttm) | -7.4 |
Return on Equity (ttm) | -31.5 |
Wed, 24 Apr 2024
Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Mon, 15 Apr 2024
MYGN Makes Notable Cross Below Critical Moving Average - Nasdaq
Tue, 09 Apr 2024
Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing - Yahoo Finance
Tue, 09 Apr 2024
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now - Yahoo Finance
Wed, 27 Mar 2024
Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay - Yahoo Finance
Wed, 20 Mar 2024
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device - Yahoo Finance
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |